With your drug remdesivir receiving FDA approval for Covid-19 treatment, what is the process for getting approval for its usage in the GCC?
The US Food and Drug Administration approval for remdesivir was granted on October 22, 2020. In the GCC, we initiated discussions with national regulatory authorities in May 2020 to identify the most appropriate regulatory pathways for the registration of remdesivir. The current authorisations are at the federal level in each of the GCC countries, with approval already received in the UAE and emergency use authorisation in place in other GCC countries including Saudi Arabia, where the process for a full marketing authorisation approval by the Saudi Food and Drug Authority is in its final step.
While Covid-19 vaccines are receiving heightened attention, are there also several treatment options undergoing trials worldwide?
Continue reading your story on the app
Continue reading your story in the magazine
It hasn’t even been a full year that Stellantis, one of the world’s biggest auto companies, has been in existence. Still, its wheels are spinning furiously. Here’s what it has in store for the region
Purpose through corporate responsibility
Every organisation must deeply reflect about whether they are leaving behind a legacy or a liability, says Abdulaziz AlSowailim, EY MENA chairman and CEO
Analysing the layers of a coconut
When we have a sense of clarity as to our purpose in life, then we institute the correct practices and habits around us, and set realistic and achievable results
DUNES TO DOMINION
FOR A COUNTRY RICH IN TRADITION AND DRIVEN BY AMBITION, THE UAE’S JOURNEY DURING THE PAST 50 YEARS HAS BEEN UNPRECEDENTED. WHAT’S IN STORE FOR THE NEXT 50?
International investors are boosting Dubai’s residential property market, which has rebounded strongly from the Covid crisis, writes Aarti Nagraj
CHASING THE AMERCIAN DREAM
FOR SHAI ZAMANIAN, THE US IS A LAND OF LIMITLESS POSSIBILITIES, AN AVENUE HE AIMS TO OPEN FOR FAMILIES WORLDWIDE VIA IMMIGRATION. HERE’S HOW HE IS BRINGING HIS GOAL TO FRUITION
OBITUARY: JOCELYN HENDERSON (1921-2021)
THE GRANDE DAME OF ABU DHABI – THE WIFE OF A FORMER DIPLOMAT – PASSED AWAY IN THE UAE CAPITAL AGED 100
THE DIGITAL DISRUPTORS
IN THE COMING YEARS, THE GCC IS EXPECTED TO PLAY A SIGNIFICANT ROLE IN SECTORS SUCH AS HEALTHCARE, MANUFACTURING, EDUCATION AND RETAIL, WHICH WILL HELP BOOST THE GROWTH OF ITS NON-OIL ECONOMY
Signed, sealed, delivered
Nicolas Baretzki, CEO of Montblanc, partnered with one of the world’s most recognisable luxury brands, Ferrari, earlier this year. Here’s where the partnership, and the German company as well, is headed next
UP, UP AND AWAY
AS THE FIRST IN-PERSON AIRSHOW TO TAKE PLACE SINCE THE OUTBREAK OF THE PANDEMIC, THE EVENT SAW SEVERAL DEALS ANNOUNCED
The Next Abortion Battle
If the Supreme Court reverses Roe v. Wade, the fight will shift to access to the abortion pill
THE ABORTION PILL'S EXILE IN OBSCURITY
Twenty-one years after its approval by the FDA, mifepristone could—but probably won’t— revolutionize a post-Roe world
Covid's Unseen Victims
Extra duties and depleted ranks have pharmacy workers buckling under the pressure
"An expert translates the jargon on your furry friend's food packaging so you know just which bag to put in your cart."
Covid Pills Face a Truth Problem
Merck’s new medicine is set to enter a landscape where misinformation is widespread
The Future of...Fixing Pharmaceuticals
Eric Edwards is cofounder and chief executive officer of Phlow, a public benefit pharmaceutical corporation. He previously co-founded pharmaceutical company Kaléo, where, among other roles, he was responsible for overall scientific strategy and pharmaceutical development programs. Following an unprecedented year for the pharmaceutical industry, including leaps in vaccine technology and supply chain shortages, Inc. asked Edwards to share his vision for the future of pharmaceuticals.
Ready Aim Omicron!
Drugmakers always knew variants would arise. The latest will test their preparedness
Prescription for 2022 - These Health Care Stocks Should Thrive
Pharmaceutical and health sciences firms are riding powerful demographic trends amid a golden age of innovation.
Playing Catchup on COVID
Scientists are testing new antiviral drugs, but they won’t be ready in time for the current wave of cases
Finally, a Drug for Alzheimer's?
After scores of failed drugs, the FDA is set to rule on a controversial candidate